Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
gene therapy
2
×
life sciences
national blog main
national top stories
new york blog main
san diego blog main
san francisco blog main
acetylon pharmaceuticals
ambys medicines
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
cell therapy
clinical trials
constellation pharmaceuticals
deals
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
genentech
holger willenbring
ipo
jeffrey tong
joshua brumm
juan carlos izpisua belmonte
kaleido biosciences
keith dionne
liver disease
markus grompe
martin burke
muscular dystrophy
myotonic dystrophy type 1
new york top stories
oregon stem cell center
What
diseases
2
×
medicines
2
×
ago
aiming
ambys
big
biotech
biotechs
considering
control
data
deadly
deal
debuted
drug
dyne
early
expected
experimental
eyes
formed
future
genetic
having
humans
ipo
ipos
launch
liver
long
make
muscle
new
rare
reach
startup
takeda
therapeutics
today
treatments
Language
unset
Current search:
medicines
×
diseases
×
" gene therapy "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
